Browse EV MemProt Atlas
- Frequency:
- literature support frequency.
- EVMP score:
annotation confidence score.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40
| UniProt ID | Protein names | Protein classification | Transmembrane count | Related Diseases | Mediation categories | Download | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| SERC2 | Q96SA4 | Serine incorporator 2 (Tumor differentially expressed protein 2-like) | Predicted membrane proteins | 11 | Metabolism mediation | 2 | 0.50 | |||
| SI1L3 | O60292 | Signal-induced proliferation-associated 1-like protein 3 (SIPA1-like protein 3) (SPA-1-like protein 3) | Disease related genesHuman disease related genesPredicted intracellular proteins | Fusion and delivery mediationReceptor-signaling mediation | 2 | 0.50 | ||||
| SLIK6 | Q9H5Y7 | SLIT and NTRK-like protein 6 | Disease related genesHuman disease related genesPredicted membrane proteins | 1 | Bladder cancerUreteral cancer | Clinical-translation mediation | 2 | 0.50 | ||
| SMOC1 | Q9H4F8 | SPARC-related modular calcium-binding protein 1 (Secreted modular calcium-binding protein 1) (SMOC-1) | Disease related genesHuman disease related genesPredicted secreted proteins | Other mediation | 2 | 0.50 | ||||
| SO4C1 | Q6ZQN7 | Solute carrier organic anion transporter family member 4C1 (SLCO4C1) (OATP-H) (Organic anion transporter M1) (OATP-M1) (Organic anion transporting polypeptide 4C1) (OATP4C1) (Solute carrier family 21 member 20) | 12 | Cardiac arrhythmiaHeart failure | Clinical-translation mediationFusion and delivery mediationImmune mediation | 2 | 0.50 | |||
| SPP2B | Q8TCT7 | Signal peptide peptidase-like 2B (SPP-like 2B) (SPPL2b) (EC 3.4.23.-) (Intramembrane protease 4) (IMP-4) (Presenilin homologous protein 4) (PSH4) (Presenilin-like protein 1) | EnzymesPredicted membrane proteins | 9 | Fusion and delivery mediationReceptor-signaling mediation | 2 | 0.50 | |||
| SPRE3 | Q2MJR0 | Sprouty-related, EVH1 domain-containing protein 3 (Spred-3) | Clinical-translation mediationReceptor-signaling mediation | 2 | 0.50 | |||||
| SPTC2 | O15270 | Serine palmitoyltransferase 2 (EC 2.3.1.50) (Long chain base biosynthesis protein 2) (LCB 2) (Long chain base biosynthesis protein 2a) (LCB2a) (Serine-palmitoyl-CoA transferase 2) (SPT 2) | 1 | Metabolism mediation | 2 | 0.50 | ||||
| SSR3 | P32745 | Somatostatin receptor type 3 (SS-3-R) (SS3-R) (SS3R) (SST3) (SSR-28) | FDA approved drug targetsG-protein coupled receptorsPredicted membrane proteinsTransporters | 7 | Alzheimer diseaseCushing syndromeStomach cancer | Clinical-translation mediationReceptor-signaling mediation | 2 | 0.50 | ||
| STYK1 | Q6J9G0 | Tyrosine-protein kinase STYK1 (EC 2.7.10.2) (Novel oncogene with kinase domain) (Protein PK-unique) (Serine/threonine/tyrosine kinase 1) | EnzymesPredicted intracellular proteinsPredicted membrane proteins | 1 | Other mediation | 2 | 0.50 | |||
| TIMD4 | Q96H15 | T-cell immunoglobulin and mucin domain-containing protein 4 (TIMD-4) (T-cell immunoglobulin mucin receptor 4) (TIM-4) (T-cell membrane protein 4) | Plasma proteinsPredicted membrane proteins | 1 | Clinical-translation mediationImmune mediation | 2 | 0.50 | |||
| TLR4 | O00206 | Toll-like receptor 4 (hToll) (CD antigen CD284) | CD markersFDA approved drug targetsHuman disease related genesPredicted intracellular proteinsPredicted membrane proteinsTransporters | 1 | Allergic/hypersensitivity disorderDiabetes mellitusHepatitis virus infectionMalignant haematopoietic neoplasmMelanomaProstate cancerSepsisSolid tumour/cancer | Clinical-translation mediationFusion and delivery mediationImmune mediationMetabolism mediationReceptor-signaling mediation | 2 | 0.50 | ||
| TM101 | Q96IK0 | Transmembrane protein 101 (Putative NF-kappa-B-activating protein 130) | 8 | Immune mediationReceptor-signaling mediation | 2 | 0.50 | ||||
| TM139 | Q8IV31 | Transmembrane protein 139 | Predicted membrane proteinsTransporters | 1 | Other mediation | 2 | 0.50 | |||
| TMC5A | Q8N6Q1 | Transmembrane and coiled-coil domain-containing protein 5A | Predicted intracellular proteinsPredicted membrane proteins | 1 | Other mediation | 2 | 0.50 | |||
| TMPS2 | O15393 | Transmembrane protease serine 2 (EC 3.4.21.122) (Serine protease 10) [Cleaved into: Transmembrane protease serine 2 non-catalytic chain; Transmembrane protease serine 2 catalytic chain] | Cancer-related genesEnzymesPredicted intracellular proteinsPredicted membrane proteinsPredicted secreted proteinsTransporters | 1 | COVID-19Middle East Respiratory SyndromeSevere acute respiratory syndrome | Clinical-translation mediationMetabolism mediation | 2 | 0.50 | ||
| TR10D | Q9UBN6 | Tumor necrosis factor receptor superfamily member 10D (Decoy receptor 2) (DcR2) (TNF-related apoptosis-inducing ligand receptor 4) (TRAIL receptor 4) (TRAIL-R4) (TRAIL receptor with a truncated death domain) (CD antigen CD264) | 1 | Immune mediation | 2 | 0.50 | ||||
| TRPV3 | Q8NET8 | Transient receptor potential cation channel subfamily V member 3 (TrpV3) (Vanilloid receptor-like 3) (VRL-3) | 6 | DepressionDiabetes mellitusPain | Clinical-translation mediationFusion and delivery mediation | 2 | 0.50 | |||
| UBP14 | P54578 | Ubiquitin carboxyl-terminal hydrolase 14 (EC 3.4.19.12) (Deubiquitinating enzyme 14) (Ubiquitin thioesterase 14) (Ubiquitin-specific-processing protease 14) | EnzymesMetabolic proteinsPlasma proteinsPredicted intracellular proteins | Neurodegenerative disorderSolid tumour/cancer | Clinical-translation mediationImmune mediationMetabolism mediation | 2 | 0.50 | |||
| UPAR | Q03405 | Urokinase plasminogen activator surface receptor (U-PAR) (uPAR) (Monocyte activation antigen Mo3) (CD antigen CD87) | Cancer-related genesCD markersFDA approved drug targetsPredicted intracellular proteinsPredicted membrane proteins | Acquired hypomelanotic disorderAtopic eczemaMyeloproliferative neoplasmPancreatic cancerThrombocytosis | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediationImmune mediationMetabolism mediationReceptor-signaling mediation | 2 | 0.50 | |||
| UTRN | P46939 | Utrophin (Dystrophin-related protein 1) (DRP-1) | Plasma proteinsPredicted intracellular proteins | Muscular dystrophy | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 2 | 0.50 | |||
| ZMY10 | O75800 | Zinc finger MYND domain-containing protein 10 (Protein BLu) | Fusion and delivery mediation | 2 | 0.50 | |||||
| ZNT1 | Q9Y6M5 | Proton-coupled zinc antiporter SLC30A1 (Solute carrier family 30 member 1) (Zinc transporter 1) | Metabolic proteinsPredicted membrane proteinsTransporters | 6 | Fusion and delivery mediationMetabolism mediation | 2 | 0.50 | |||
| AB1IP | Q7Z5R6 | Amyloid beta A4 precursor protein-binding family B member 1-interacting protein (APBB1-interacting protein 1) (Proline-rich EVH1 ligand 1) (PREL-1) (Proline-rich protein 73) (Rap1-GTP-interacting adapter molecule) (RIAM) (Retinoic acid-responsive proline-rich protein 1) (RARP-1) | Predicted intracellular proteins | Adhesion and uptake mediationClinical-translation mediationImmune mediationReceptor-signaling mediation | 1 | 0.50 | ||||
| ABCAC | Q86UK0 | Glucosylceramide transporter ABCA12 (EC 7.6.2.1) (ATP-binding cassette sub-family A member 12) (ATP-binding cassette transporter 12) (ATP-binding cassette 12) | 14 | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediationMetabolism mediation | 1 | 0.50 |